Disease Markers

Research Article

Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis

Table 1

The baseline characteristics of eligible clinical researches.
AuthorCountryNo.VectorT cell originCell cultureTransfection methodT cell treatmentT cell persistenceDiagnosisTargetTransduction efficiencyLymph depletionIL-2 for patientT cell doseResponseRef
Donald (2017)USA10CD8+CD3ζAutologousNALentiviralIrradiated+IL-21 dayGlioblastomaEGFRvIII19.75%NoNo~, [5]
Gregory (2018)USA6CD3ζ+CD28Autologous8~12 daysLentiviralNA1 dayPancreatic carcinomaMesothelin90.7% (76.9~95.9%)NoNo1~/m2, [14]
Juiie (2006)USA6CD4+CD3Autologous14 daysLentiviralOKT3+IL2+irradiated7 daysNeuroblastomaCE7RNAYesNo108~109/m2, [13]
Chrystal (2018)USA1914.G2a-zAutologous18~23 daysRetroviralOKT3+IL2+irradiated6 weeksNeuroblastomaGD2+EBV+NANoNo~/m2, , , , , nuosis[4]
Christine (2015)USA3CD4+CD3+GM-CSFAutologous14 daysCytomegalovirusOKT3+IL2+irradiated>6 weeksGlioblastomaIL13Rα2>75%YesNo96~, [12]
Kaichao (2016)China11CD137+CD8+CD3ζAutologous10~13 daysLentiviralIL-2>4 weeksNSCLCEGFR29.28% (20.87~31.22%)YesYes0.45~, , [26]
Kaichao (2017)China1CD137+CD3ζAutologous2 daysLentiviralIL-22 monthsCholangiocarcinomaEGFR+CD133NANoNo/kgPR[16]
Nabil (2017)USA17FRP5+CD28Autologous3~4 weeksRetroviralNA1 yearGlioblastomaHER239%NoNo106~108/m2, , [9]
Nabil (2015)USA19FRP5+CD28Autologous10~21 daysRetroviralIL-2+OKT3>6 weeksSarcomaHER265.2% (36.2~88%)NoNo~/m2, , , [19]
Chengcheng (2017)China10IgG4+CD28+CD3zAutologous14~16 daysLentiviralIL-24~6 weeksColorectal cancersCEA33.7% (14.7%~43.2%)YesNo~/kg, [23]
Steven (2015)USA6CD28+CD3ζAutologous10~14 daysRetroviralOKT3+IL-2NALiver metastasesCEA45% (10%~64%)NoYes~, [14]
Kaichao (2017)China11CD137+CD3ζAutologous12 daysLentiviralOKT3+IL-2+IFN4 weeksBiliary tract and pancreatic cancersHER29.9% (5.5%~11.4%)YesNo/kg (1.4~/kg), , [17]
Richard (2016)USA5—Autologous14 daysRetroviralOKT3+IL-23 weeksProstate cancerPSMA5~56%YesYes109~1010, , [24]
Fiona (2017)UK14CD3ζ+MFEζAutologous7 daysRetroviralOKT3+IL-214 daysGastrointestinal malignanciesCEACAM526.9% (20.1~37.3%)YesYes109~, [25]
Laura (2009)USA20TCR-β+TCR-αAutologous9~12 daysRetroviralOKT3+IL2+irradiated4 weeksMetastatic melanomaDMF571% (33~95%)YesYes2~, [21]
16TCR-β+TCR-αAutologous9~12 daysRetroviralOKT3+IL2+irradiated4 weeksMetastatic melanomaGp10082% (55~97%)YesYes2.3~, , [21]
Christine E.USA14-1BB+CD19Autologous<14 daysLentiviralrhIL-2+rhIL-15<4 weeksGlioblastomaIL13Rα274%~90%NoNo[11]
Yao WangChina23CD137+CD3zAutologous<14 daysLentiviralIL-24 weeksHCC, PC, CRCCD13311.23%~56.47%NoNo0.5~/kg, , [27]
JuliaUSA6CD3εAutologous8~12 daysElectroporationNA<14 daysBreast cancerc-Met36.5%~85.8%NoNo~, , [25]
S. RosenbergUSA24CD3AutologousNARetroviralNANAMetastatic melanoma and renal cancerVEGFR2NAYesYes106~, , NCT 01218867
Hegde M.USA6CD28AutologousNANANA6 weeksSarcomaHER2NAYesNA/m2, , [20]
Zhai B.China5NANANALentiviralNANAHepatocellularGPC3NANoNA~/kg[18]
8NANANALentiviralNANACarcinomaGPC3NAYesNA~, , [18]
Ahmed N. M.USA15CD28.zetaAutologousNANANA12 weeksGlioblastomaHER267% (46%~82%)NoNA~/m2, , [10]
SD: stable disease; PD: progressive disease; PR: partial response; CR: complete response; NED: no evidence of disease; NR: no response; MR: minor response; NE: not evaluable.